Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06521463 · ClinicalTrials.gov registry record · NA
SIMPLAAFY Clinical Trial
A NA study of Stroke and Atrial Fibrillation, sponsored by Boston Scientific Corporation.
- Active
- Registry status
- NA
- Development phase
- 1,857
- Enrollment target
- 20
- Study locations
NCT06521463 is a NA study of Stroke and Atrial Fibrillation that is active but no longer recruiting, run by Boston Scientific Corporation. The registered enrollment target is 1,857 participants, below the 12,012-participant average among 454 other Stroke trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT06521463, a NA study of Stroke and Atrial Fibrillation, is active but no longer recruiting, sponsored by Boston Scientific Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,857 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.
Conditions Studied
Interventions
- DEVICE WATCHMAN FLX Pro LAAC Device
Study Locations (20)
California
- Mills Peninsula Health Services - Burlingame
- John Muir Medical Center - Concord
- Scripps Memorial Hospital - La Jolla
- Loma Linda University Medical Center - Loma Linda
- St. John's Health Center - Los Angeles
- Santa Barbara Cottage Hospital - Santa Barbara
- Los Robles Hospital & Medical Center - Thousand Oaks
- Cardiology Associates Medical Group - Ventura
Arizona
- Phoenix Cardiovascular Research Group - Phoenix
- HonorHealth Heart Group - Shea - Scottsdale
- Tucson Medical Center Healthcare - Tucson
Alabama
- University of Alabama Birmingham - Birmingham
- Grandview Medical Center - Birmingham
Colorado
- Colorado Heart and Vascular PC - Lakewood
- Medical Center of the Rockies - Loveland
Florida
- Baptist Medical Center - Jacksonville
- HCA Florida Mercy Hospital - Miami
Arkansas
- Arrhythmia Research Group - Jonesboro
Connecticut
- Hartford Hospital - Hartford
District of Columbia
- Washington Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,857 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2027-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06521463
The ClinicalTrials.gov registry entry for NCT06521463 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 1,857 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,012-participant average among 454 other Stroke trials with a reported enrollment target (85% lower). The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which WATCHMAN FLX Pro LAAC Device is the first listed.
NCT06521463 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT06521463 about?
NCT06521463 is a clinical study titled "SIMPLAAFY Clinical Trial". The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.
What is the current status of trial NCT06521463?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,857 participants. The study started on 2024-10-01. Estimated completion is 2027-01.
What conditions does trial NCT06521463 study?
This clinical trial studies the following conditions: Stroke, Atrial Fibrillation, Bleeding.
What interventions are being tested in trial NCT06521463?
The interventions under investigation include: WATCHMAN FLX Pro LAAC Device (DEVICE).
Who is sponsoring clinical trial NCT06521463?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06521463 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tracking a Tactile Signal Along the Nervous System
RECRUITING · NA
-
Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia
RECRUITING · NA
-
Strategy Training for Individuals With Unilateral Neglect
RECRUITING · NA
-
Weight Loss and ExeRcise
RECRUITING · NA
-
Safety and Feasibility of an ExoNET for Supination Assistance for Stroke Survivors
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.